These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36496303)

  • 21.
    De Leo A; de Biase D; Lenzi J; Barbero G; Turchetti D; Grillini M; Ravegnini G; Angelini S; Zamagni C; Coluccelli S; Dondi G; De Iaco P; Perrone AM; Tallini G; Santini D; Ceccarelli C
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evolving role of morphology in endometrial cancer diagnostics: From histopathology and molecular testing towards integrative data analysis by deep learning.
    Fremond S; Koelzer VH; Horeweg N; Bosse T
    Front Oncol; 2022; 12():928977. PubMed ID: 36059702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice.
    de Biase D; Maloberti T; Corradini AG; Rosini F; Grillini M; Ruscelli M; Coluccelli S; Altimari A; Gruppioni E; Sanza V; Turchetti D; Galuppi A; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; De Leo A
    Front Med (Lausanne); 2023; 10():1146499. PubMed ID: 37064027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis.
    Travaglino A; Raffone A; Santoro A; Raimondo D; Angelico G; Valente M; Arciuolo D; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Seracchioli R; Zannoni GF
    Gynecol Oncol; 2021 Sep; 162(3):804-808. PubMed ID: 34266691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
    Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
    Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort.
    Knez J; Sobocan M; Belak U; Kavalar R; Zupin M; Büdefeld T; Potocnik U; Takac I
    Radiol Oncol; 2021 Sep; 56(1):76-82. PubMed ID: 34529911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
    Vermij L; Jobsen JJ; León-Castillo A; Brinkhuis M; Roothaan S; Powell ME; de Boer SM; Khaw P; Mileshkin LR; Fyles A; Leary A; Genestie C; Jürgenliemk-Schulz IM; Crosbie EJ; Mackay HJ; Nijman HW; Nout RA; Smit VTHBM; Creutzberg CL; Horeweg N; Bosse T;
    Br J Cancer; 2023 Mar; 128(7):1360-1368. PubMed ID: 36690721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study.
    Yamashita R; Long J; Longacre T; Peng L; Berry G; Martin B; Higgins J; Rubin DL; Shen J
    Lancet Oncol; 2021 Jan; 22(1):132-141. PubMed ID: 33387492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
    Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.
    Talhouk A; Derocher H; Schmidt P; Leung S; Milne K; Gilks CB; Anglesio MS; Nelson BH; McAlpine JN
    Clin Cancer Res; 2019 Apr; 25(8):2537-2548. PubMed ID: 30523022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
    Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
    Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of artificial intelligence with deep learning of hematoxylin and eosin-stained whole slide images to predict lymph node metastasis in T1 colorectal cancer using endoscopically resected specimens; prediction of lymph node metastasis in T1 colorectal cancer.
    Song JH; Hong Y; Kim ER; Kim SH; Sohn I
    J Gastroenterol; 2022 Sep; 57(9):654-666. PubMed ID: 35802259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Profiling of Endometrial Cancer: An Exploratory Study in Aotearoa, New Zealand.
    Henry CE; Phan K; Orsman EJ; Kenwright D; Thunders MC; Filoche SK
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
    van den Heerik ASVM; Aiyer KTS; Stelloo E; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Mens JWM; van der Steen-Banasik EM; Creutzberg CL; Smit VTHBM; Horeweg N; Bosse T
    Gynecol Oncol; 2022 Sep; 166(3):530-537. PubMed ID: 35840357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
    Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
    Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piloting a Deep Learning Model for Predicting Nuclear BAP1 Immunohistochemical Expression of Uveal Melanoma from Hematoxylin-and-Eosin Sections.
    Zhang H; Kalirai H; Acha-Sagredo A; Yang X; Zheng Y; Coupland SE
    Transl Vis Sci Technol; 2020 Sep; 9(2):50. PubMed ID: 32953248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
    Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z
    J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images.
    Sadhwani A; Chang HW; Behrooz A; Brown T; Auvigne-Flament I; Patel H; Findlater R; Velez V; Tan F; Tekiela K; Wulczyn E; Yi ES; Mermel CH; Hanks D; Chen PC; Kulig K; Batenchuk C; Steiner DF; Cimermancic P
    Sci Rep; 2021 Aug; 11(1):16605. PubMed ID: 34400666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.